DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Dr - 2 Zepbound - 2 Sally Seymour - 1 ” Patrik Jonsson - 1 Lilly Cardiometabolic - 1 Jonsson - 1 Lilly - 1
Top related locs:
FDA’s U.S
Top related orgs:
CNN - 1 Food and Drug Administration - 1 FDA - 1 American Academy of Sleep - 1 OSA - 1 New England - 1 of Medicine - 1 BMI - 1

Search resuls for: "Lilly Cardiometabolic"


2 mentions found


☆ FDA approves weight-loss drug Zepbound for obstructive sleep apnea
  + stars: | 2024-12-20 | by ( Meg Tirrell | ) edition.cnn.com   time to read: +5 min
CNN —The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. “This is a major step forward for patients with obstructive sleep apnea,” Dr. Sally Seymour, director of the FDA’s Division of Pulmonology, Allergy, and Critical Care, said in the FDA announcement. Obstructive sleep apnea, or OSA, affects as many as 30 million people in the USand is closely associated with obesity, according to the American Academy of Sleep Medicine, which notes that weight loss can reduce its severity. It’s characterized by breathing disruptions during sleep caused by blocked airflow and increases the risk of heart and brain problems. Patients on the drug also saw reductions in blood pressure and inflammation, “important risk factors for cardiovascular complications of obstructive sleep apnea with obesity,” researchers wrote in the New England Journal of Medicine.
Persons: Eli Lilly, Dr, Sally Seymour, ” Patrik Jonsson, Lilly Cardiometabolic, Jonsson, Lilly, Biden, they’re, Sanjay Gupta, Zepbound Organizations: CNN, Food and Drug Administration, FDA, American Academy of Sleep, OSA, New England, of Medicine, BMI, CNN Health Locations: FDA’s
☆ Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
  + stars: | 2024-12-04 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk 's Wegovy, in the first head-to-head clinical trial on the weekly injections. Eli Lilly said Zepbound provided a 47% higher relative weight reduction compared with Wegovy in the trial. Separate studies on the drugs, along with a recent head-to-head analysis of health records, have similarly implied that Zepbound outperforms Wegovy in terms of weight loss. Eli Lilly is still evaluating the results, which it plans to publish in a peer-reviewed journal and present at a medical meeting next year. Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the booming weight loss drug market.
Persons: Eli Lilly, Zepbound, Wegovy, Dr, Leonard Glass, Eli Lilly Cardiometabolic Organizations: Novo Nordisk, and Drug Administration Locations: U.S
0 next >>
Total: 2